Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative prophylactic intraperitoneal chemotherapy after curative surgery for advanced gastric cancer
ChiCTR-IIR-17013434Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 5-fluorouracil + nab-paclitaxel + cisplatin + interleukin-2 and adjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoints: Intraperitoneal chemotherapy-related safety and Morbidity. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
5-fluorouracil + nab-paclitaxel + cisplatin + interleukin-2adjuvant chemotherapy
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-IIR-17013434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013434.